Clinical Real-World Data Bolsters Neuromod Devices’ Lenire Tinnitus Therapy

According to a recent LinkedIn post from Neuromod Devices Ltd, MassDevice has covered a second real‑world analysis of U.S. tinnitus patients treated with its Lenire device. The post highlights a paper by Dr. Craig Kasper of NYHD | Institute for Hearing & Balance, reporting that 81.8% of 140 patients experienced tinnitus relief and a mean reduction of 23.8 points on the THI scale.

The company’s LinkedIn post suggests these outcomes are consistent with findings from an earlier U.S. real‑world analysis published in Nature Portfolio. For investors, repeated evidence of clinically meaningful benefit, now also featured in ASHA Journals coverage, may support Neuromod Devices’ efforts to drive clinician adoption, reinforce reimbursement arguments, and strengthen the commercial opportunity around its FDA‑approved tinnitus therapy.

If these results continue to be replicated in broader populations, Neuromod Devices could enhance its competitive position in the tinnitus and hearing‑care market. The visibility via MassDevice and peer‑reviewed outlets may also improve brand recognition among audiologists and ENT specialists, potentially supporting long‑term revenue growth and positioning the company for future partnerships or capital raising in the medtech sector.